Full Press Release Details
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413.
KYMR
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413
Key Takeaway: Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413
Price reaction · baseline $53.92 (2021-11-29 close) · hit after-hours · clean, no other KYMR news in the window
day 0 close · peak
+3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
4.3%
average across 7 past catalysts
Cash runway
~83 mo
Minimal dilution risk
Lead asset
KT-621
Phase 2 · Atopic Dermatitis